Conclusion
Through this case, we demonstrate the importance of involving
multidisciplinary team in decision making, as balancing maternal
complications as well as reassuring fetal wellbeing during such critical
period is imperative. We have thus confirmed the feasibility of using
convalescent plasma and ECMO during early postnatal period in critically
ill obstetric patients with respiratory failure. The use of tocilizumab,
convalescent plasma, followed by intensive care management with
intubation and ECMO might have potentially contributed to the complete
recovery of the mother and the newborn. Whether
antimalarials-hydroxychloroquine (in particular), and/or antivirals are
effective in treating COVID-19 - remains unknown. Further well-defined
studies are necessary to study the effectiveness and safety of plasma
transfusion in COVID-19 patients.